Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI).

P. Daley-Yates (Greenford, United Kingdom)

Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Session: Novel mechanisms and treatments for asthma
Session type: Oral Presentation
Number: 276
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Daley-Yates (Greenford, United Kingdom). Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI).. 276

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Use of exhaled nitric oxide (eNO) as a marker for anti-inflammatory dose-response of beclomethasone extrafine aerosol (Q) dosed once daily (50-100μg) in children with exercise-induced (EI) asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009

Late Breaking Abstract - Management of asthma in pregnancy using fractional exhaled nitric oxide (FENO) to adjust inhaled corticosteroid (ICS) dose did not improve perinatal outcomes: the Breathing for Life Trial (BLT)
Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers
Year: 2020


Influence of fluticasone propionate on levels of exhaled nitric oxide in asthmatic children: a dose response study
Source: Eur Respir J 2001; 18: Suppl. 33, 40s
Year: 2001

Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels
Source: International Congress 2017 – Monitoring asthma control
Year: 2017

Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016

Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes?
Source: International Congress 2018 – Clinical and functional monitoring in airway disease
Year: 2018

Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013

Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children
Source: Eur Respir J 2004; 24: Suppl. 48, 270s
Year: 2004

Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children
Source: Eur Respir J 2002; 20: 630-634
Year: 2002



Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study
Source: Eur Respir J 2006 Oct 01;28(4):748-755
Year: 2006



Exhaled nitric oxide (FENO) in the assessment of the safety of allergen immunotherapy (SIT) in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

Effect of systemic and extra-fine particle inhaled corticosteroids on corrected alveolar nitric oxide (CANO) in COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Stability of exhaled nitric oxide (FENO) in patients with severe, steroid-dependent asthma
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008


Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Dose response to inhaled fluticasone/salmeterol measured with extended exhaled nitric oxide in refractory asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA)
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020


Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma
Source: Eur Respir J 2001; 18: 635-639
Year: 2001